OncoMatch/Clinical Trials/NCT02977780
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Is NCT02977780 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for glioblastoma.
Treatment: Temozolomide · Neratinib · QBS10072S · Abemaciclib · CC-115 — This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currently closed to accrual) * QBS10072S
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 R132H (immunohistochemically negative)
Immunohistochemically negative for IDH1 R132H mutation
Required: MGMT promoter unmethylated
Evidence that the tumor MGMT promoter is unmethylated by standard of care assays
Prior therapy
Must have received: surgery
Participants may have had prior surgery for glioblastoma or gliosarcoma but no systemic or radiation therapy
Cannot have received: systemic therapy
no systemic or radiation therapy
Cannot have received: radiation therapy
no systemic or radiation therapy
Cannot have received: cranial radiotherapy
Participants who have had any prior cranial radiotherapy
Lab requirements
Blood counts
Leukocytes ≥3,000/mL; Absolute neutrophil count ≥1,500/mL; Platelets ≥100,000/mL; Hemoglobin ≥ 9g/dl
Kidney function
Creatinine ≤ institutional upper limit of normal OR Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal
Liver function
Total bilirubin within normal institutional limits (except for participant's with Gilbert's disease); AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal
Cardiac function
INR < 2.0; PTT ≤ institutional upper limit of normal, unless receiving therapeutic low molecular weight heparin; QTc interval > 450 ms for men or > 470 ms for women; Complete left bundle branch or bifascicular block; Persistent or history of clinically meaningful ventricular arrhythmias or atrial fibrillation; Unstable pectoris or myocardial infarction ≤ 3 months prior to starting study treatment; Uncontrolled hypertension (blood pressure ≥ 160/95 mmHg); Other clinically significant heart disease such as congestive heart failure requiring treatment
Participants must have normal organ and marrow function as defined below: Leukocytes ≥3,000/mL; Absolute neutrophil count ≥1,500/mL; Platelets ≥100,000/mL; Hemoglobin ≥ 9g/dl; Total bilirubin within normal institutional limits (except for participant's with Gilbert's disease); AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal; Creatinine ≤ institutional upper limit of normal OR Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal; Potassium within normal institutional range, or correctable with supplements; Serum amylase ≤ 1.5 x institutional upper limit of normal; Serum lipase ≤ 1.5 x institutional upper limit of normal; INR < 2.0; PTT ≤ institutional upper limit of normal, unless receiving therapeutic low molecular weight heparin
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- Massachusetts General Hospital · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
- Mayo Clinic · Rochester, Minnesota
- Columbia University Medical Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02977780 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require IDH1?
Yes, IDH1 R132H is a required biomarker for enrollment.
Does this trial require MGMT?
Yes, MGMT promoter unmethylated is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify